Dysfunctional Uterine Bleeding (DUB) is heavy or irregular bleeding that is often painless and not caused by another abnormality (like gynecological infections, fibroid lesions or tumors). DUB is the most common menstrual disorder affecting women of reproductive age. Approximately 10% of American women between the ages of 12 and 52 are affected by DUB. It’s estimated that 16 million American women have been affected by DUB at some point in their lives. 20% of all women worldwide are estimated to be suffering from DUB.
Healthcare providers must rule out other reasons for heavy or irregular bleeding prior to confirming a diagnosis of DUB. Tests to diagnose DUB begin after frequency, duration and amount of excess bleeding have been reviewed by the healthcare professional. A pelvic examination, urine tests, blood tests and possibly an ultrasound or biopsies may be conducted to determine causes for the symptoms.
Treatment typically depends upon the underlying cause and the age of the patients. The initial focus of DUB treatment is to control the bleeding. Several different treatment options are available for those suffering from DUB. They range from drug therapies to surgical intervention designed to temporarily control and/or reduce bleeding, to a hysterectomy (removal of the uterus) to eliminate menstruation completely. Women experiencing heavy menstrual flow should consult with their medical provider to determine a diagnosis and a course of therapy that works best for their condition.
FemmePharma Global Healthcare, Inc. is committed to helping women with DUB by researching and developing safe, new and effective pharmaceutical treatment options.